Curis Lifesciences IPO Analysis
08 November 2025
As Curis Lifesciences hits the SME IPO market, investors are weighing its science-led edge against modest scale and operational depth — a test of whether innovation can convert to investor conviction.
Here’s what Curis Lifesciences is bringing to the table:
Industry Overview
India’s pharmaceutical industry stands as the third-largest globally by volume and fourteenth by value, built on its strength in generics and branded generics, which account for nearly 70% of the market. The rest is driven by APIs (~20%) and contract manufacturing (~10%), segments that typically operate within 14–22% margin ranges.
Curis Lifesciences sits within this formulation in the contract manufacturing segment—a cost-competitive, low-IP segment where scale and efficiency outweigh innovation.
Overall, the Indian pharma sector contributes about 1.7% to GDP, with a market size of ~$50 billion, expected to more than double to $120–130 billion by 2030, powered by government incentives, export growth, and a maturing R&D base.
Powered by Froala Editor
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.